The critical problem with traditional cancer treatments targeting wildtype p53 is that almost fifty to sixty percent of all cancers have at least one mutated copy of p53 making them resistant to treatments with wildtype p53-directed therapies (Kandoth et al., 2013). Here, TP53 is linked to cancer.